The single shot variant of Russia’s coronavirus vaccine, Sputnik Light, has been approved for use in India.
At a stroke, the decision doubles the number of people in the world who can receive protection from the shot, which has now been registered in around 30 countries.
A number of countries are also using the vaccine as a booster for people who have received either the regular two-shot Sputnik V vaccine, or another product.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze